Survey: Cards say Lipitor, Plavix yield best results
One hundred cardiologists surveyed about companies that have had the greatest impact in the field of cardiology placed Pfizer, AstraZeneca, Johnson & Johnson, Merck and Sanofi-Aventis at the top. Additionally, cardiologists said that atorvastatin (Lipitor), clopidogrel (Plavix) and carvedilol (Coreg) yielded the best patient outcomes, reported Sermo Client Solutions, which released the results of its survey Aug. 3.
The survey included responses from 100 cardiologists in the Sermo network, most of whom treat between 50 and 150 patients per week. The respondents were asked to select the top three medical companies (pharmaceutical, biotechnology or medical devices) that they felt contributed most to cardiology over the last 20 years and the top three drugs they felt had the most impact on practice and patients.
When asked which products yielded the best outcomes, cardiologists reported big name blockbuster drugs like atorvastatin (Lipitor, 36 percent), clopidogrel (Plavix, 19 percent) and carvedilol (Coreg, 13 percent).
Additionally, 8 percent of cardiologists believed rosuvastatin (Crestor) yielded the best results, 6 percent chose dabigatran (Pradaxa), 4 percent chose simvastatin (Zocor) and 3 percent selected nebivolol (Bystolic). Meanwhile, 2 percent of cardiologists reported that valsartan (Diovan), prasugrel (Effient) and telmisartan (Micardis) yielded the best results.
Cardiologists who responded to the survey deemed Pfizer, AstraZeneca, Abbott, Johnson & Johnson, Merck and Sanofi-Aventis the most influential contributors to cardiology. The survey addressed the field of cardiology in the last 20 years in terms of research and development, delivery of products and solutions.
Cardiologists also were asked how they spend the majority of their time. Ninety-two percent of cardiologists said they spend their time in clinical practice while 7 percent said they spend their time dealing with academic responsibilities.
Sermo represents 68 specialties and is an online community of physicians. See survey results here.
The survey included responses from 100 cardiologists in the Sermo network, most of whom treat between 50 and 150 patients per week. The respondents were asked to select the top three medical companies (pharmaceutical, biotechnology or medical devices) that they felt contributed most to cardiology over the last 20 years and the top three drugs they felt had the most impact on practice and patients.
When asked which products yielded the best outcomes, cardiologists reported big name blockbuster drugs like atorvastatin (Lipitor, 36 percent), clopidogrel (Plavix, 19 percent) and carvedilol (Coreg, 13 percent).
Additionally, 8 percent of cardiologists believed rosuvastatin (Crestor) yielded the best results, 6 percent chose dabigatran (Pradaxa), 4 percent chose simvastatin (Zocor) and 3 percent selected nebivolol (Bystolic). Meanwhile, 2 percent of cardiologists reported that valsartan (Diovan), prasugrel (Effient) and telmisartan (Micardis) yielded the best results.
Cardiologists who responded to the survey deemed Pfizer, AstraZeneca, Abbott, Johnson & Johnson, Merck and Sanofi-Aventis the most influential contributors to cardiology. The survey addressed the field of cardiology in the last 20 years in terms of research and development, delivery of products and solutions.
Cardiologists also were asked how they spend the majority of their time. Ninety-two percent of cardiologists said they spend their time in clinical practice while 7 percent said they spend their time dealing with academic responsibilities.
Sermo represents 68 specialties and is an online community of physicians. See survey results here.